| Dr Shawn B Clark, MD | |
|
6701 Airport Blvd Ste D146, Mobile, AL 36608-3784 | |
| (251) 287-2176 | |
| (251) 287-2279 |
| Full Name | Dr Shawn B Clark |
|---|---|
| Gender | Male |
| Speciality | Neurosurgery |
| Experience | 31 Years |
| Location | 6701 Airport Blvd Ste D146, Mobile, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306849575 | NPI | - | NPPES |
| 120636 | Medicaid | AL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | 23993 (Alabama) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Providence Hospital | Mobile, AL | Hospital |
| Singing River Health System | Pascagoula, MS | Hospital |
| South Baldwin Regional Medical Center | Foley, AL | Hospital |
| Thomas Hospital | Fairhope, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Shawn Clark, Md, Pc | 0143459776 | 4 |
News Archive
Pfizer Inc announced that the Phase 3 INTORSECT (B1771003) study, evaluating TORISEL(temsirolimus) in patients with advanced renal cell carcinoma (RCC) whose disease had progressed on or after SUTENT (sunitinib malate) therapy, did not meet the primary endpoint of prolonging progression free survival (PFS) when compared to sorafenib.
"Amid budget crisis, a defense of foreign aid," Sen. John Kerry: "On one point we must remain resolute: This is not time for America to pull back from the world. This is a time to step forward".
Kaiser Health News staff writer Phil Galewitz reports: "Trying to spur enrollment in a new health insurance program for uninsured people with pre-existing medical conditions, the federal government is doing something private insurers almost never do: slashing rates" (Galewitz, 11/5).
A recent analysis reveals that treatment of male breast cancer has evolved over the years. In addition, certain patient-, tumor-, and treatment-related factors are linked with better survival. The findings are published early online in CANCER, a peer-reviewed journal of the American Cancer Society.
› Verified 7 days ago
| Entity Name | Shawn Clark, Md, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972931533 PECOS PAC ID: 0143459776 Enrollment ID: O20140131000697 |
News Archive
Pfizer Inc announced that the Phase 3 INTORSECT (B1771003) study, evaluating TORISEL(temsirolimus) in patients with advanced renal cell carcinoma (RCC) whose disease had progressed on or after SUTENT (sunitinib malate) therapy, did not meet the primary endpoint of prolonging progression free survival (PFS) when compared to sorafenib.
"Amid budget crisis, a defense of foreign aid," Sen. John Kerry: "On one point we must remain resolute: This is not time for America to pull back from the world. This is a time to step forward".
Kaiser Health News staff writer Phil Galewitz reports: "Trying to spur enrollment in a new health insurance program for uninsured people with pre-existing medical conditions, the federal government is doing something private insurers almost never do: slashing rates" (Galewitz, 11/5).
A recent analysis reveals that treatment of male breast cancer has evolved over the years. In addition, certain patient-, tumor-, and treatment-related factors are linked with better survival. The findings are published early online in CANCER, a peer-reviewed journal of the American Cancer Society.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Shawn B Clark, MD 6701 Airport Blvd Ste D146, Mobile, AL 36608-3784 Ph: (251) 287-2176 | Dr Shawn B Clark, MD 6701 Airport Blvd Ste D146, Mobile, AL 36608-3784 Ph: (251) 287-2176 |
News Archive
Pfizer Inc announced that the Phase 3 INTORSECT (B1771003) study, evaluating TORISEL(temsirolimus) in patients with advanced renal cell carcinoma (RCC) whose disease had progressed on or after SUTENT (sunitinib malate) therapy, did not meet the primary endpoint of prolonging progression free survival (PFS) when compared to sorafenib.
"Amid budget crisis, a defense of foreign aid," Sen. John Kerry: "On one point we must remain resolute: This is not time for America to pull back from the world. This is a time to step forward".
Kaiser Health News staff writer Phil Galewitz reports: "Trying to spur enrollment in a new health insurance program for uninsured people with pre-existing medical conditions, the federal government is doing something private insurers almost never do: slashing rates" (Galewitz, 11/5).
A recent analysis reveals that treatment of male breast cancer has evolved over the years. In addition, certain patient-, tumor-, and treatment-related factors are linked with better survival. The findings are published early online in CANCER, a peer-reviewed journal of the American Cancer Society.
› Verified 7 days ago
Jeremy W Amps, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 6701 Airport Blvd, Suite D146, Mobile, AL 36608 Phone: 251-633-5155 Fax: 251-633-5125 | |
Dr. Donald R Tyler, M. D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 3280 Dauphin St, Building A, Mobile, AL 36606 Phone: 251-450-3700 Fax: 251-662-3819 | |
Amber Shea Gordon, M.D. Neurological Surgery Medicare: May Accept Medicare Assignments Practice Location: 3 Mobile Infirmary Cir Ste 410, Mobile, AL 36607 Phone: 251-435-6850 Fax: 251-435-6859 | |
Dr. James Ronald Hirsch, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 6701 Airport Blvd Ste D146, Mobile, AL 36608 Phone: 251-287-2176 Fax: 251-287-2279 | |
Andrew Kessler Romeo, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 1601 Center St, Mobile, AL 36604 Phone: 251-660-5108 Fax: 251-660-5792 | |
Dr. Edward R Flotte, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 3280 Dauphin St, Building A, Mobile, AL 36606 Phone: 251-450-3700 Fax: 251-662-3819 |